首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1918188

多發性骨髓瘤市場－2026-2031年預測

Multiple Myeloma Market - Forecast from 2026 to 2031

出版日期: 2026年01月16日 | 出版商:

Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

多發性骨髓瘤市場預計將從 2025 年的 262.31 億美元成長到 2031 年的 376.7 億美元，複合年成長率為 6.22%。

多發性骨髓瘤市場是血液腫瘤學領域一個充滿活力且快速發展的細分市場，專注於骨髓漿細胞惡性腫瘤的治療。該疾病以高復發率和抗藥性為特徵，因此需要持續開發平臺新型治療方法，這使得該市場成為臨床研究和醫藥投資的重要中心。

核心臨床挑戰與治療模式

儘管多發性骨髓瘤仍是一種無法治癒的癌症，但其治療效果已穩步提升，治療策略的核心在於實現深度且持久的緩解、控制症狀並維持患者的生活品質。治療模式已發生巨大變化，從依賴傳統化療和糖皮質激素轉變為多管齊下的綜合治療，包括免疫調節劑、蛋白酶體抑制劑、單株抗體，以及近年來興起的先進細胞療法和雙特異性免疫療法。治療通常採用序貫給藥的方式，根據患者的病情、疾病風險分層和既往治療史選擇合適的方案，體現了複雜且個人化的治療理念。

主要市場成長促進因素

市場擴張的根本驅動力是全球疾病發生率的上升，而這與人口老化密切相關。老齡化就是一個主要的風險因素，它導致目標患者數量不斷增加，尤其是在人口老化的已開發國家。這種人口趨勢持續催生了對有效治療方法的潛在需求。

然而，最強勁的成長要素是治療方法創新和新藥認證的加速。監管環境瞬息萬變，包括靶向B細胞成熟抗原（BCMA）的治療方法在內的新型作用機制藥物不斷核准，例如雙特異性T細胞銜接器和嵌合體抗原受體（CAR）T細胞療法。這些核准持續拓展復發難治性疾病的治療選擇，並逐步納入早期治療方案。這顯著延長了治療路徑，並提升了市場價值。

疾病認知度的提高和早期診斷的普及也促進了市場成長。患者權益組織和專業協會所進行的教育活動提高了基層醫療服務提供者和公眾對疾病症狀的識別能力，從而促進了早期轉診和診斷。早期療育疾病進程可以提高有效治療的幾率，改善長期預後，使更多患者能夠積極參與長期管理。

對生物醫學研究的持續大規模投入正在推動這一市場的發展。對疾病生物學、腫瘤微環境交互作用以及抗藥性機制的深入理解，正引領一系列標靶治療和免疫療法的研發。公營和私營製藥公司的巨額資金支持著這項研究，從而營造了一個競爭激烈、創新氛圍濃厚的環境。

市場機會與不斷演變的前沿領域

未來成長的關鍵機會體現在以下幾個方面：第一線治療越來越注重早期治療，包括新診斷病例和高風險隱匿性多發性骨髓瘤，旨在阻止疾病進展。基於基因組分析和微量殘存疾病（MRD）監測的個人化治療策略的開發，為最佳化治療效果和調整治療強度提供了重要機會。

此外，隨著新興經濟體診斷和治療基礎設施的完善，市場有望進一步擴大，這主要得益於醫療資源的改善和應用範圍的擴大。探索新型藥物聯合治療和治療順序策略，以克服抗藥性並提高療效，仍然是臨床研發的核心重點。

市場限制與臨床挑戰

市場本身就存在著許多挑戰。抗藥性的出現是限制現有療法長期治療方法的根本性生物學障礙，因此需要不斷研發新型藥物。此疾病的複雜性和異質性，以及眾多的遺傳亞型，使得開發普遍有效的治療方法變得極具挑戰性。

此外，新型強效治療方法的毒性，包括細胞激素釋放症候群、神經毒性和長期血球減少症，為治療管理帶來了重大挑戰。這些毒性會影響患者的生活品質，需要專業的臨床支持，並可能限制治療方法在體弱老年患者中的應用。

區域情勢和趨勢

北美在全球多發性骨髓瘤市場佔據主導地位，這得益於其高發病率、完善的臨床試驗基礎設施（能夠快速推出新型治療方法）、有利的醫保報銷環境以及眾多大型研究機構和製藥公司的聚集。該地區通常是創新高成本治療方法的首發市場和主要收入來源。

競爭格局與策略重點

競爭環境十分激烈，既有大型跨國製藥公司，也有專業生技公司參與其中。策略活動著重於廣泛的研發，以開發下一代治療方法，包括新型CAR-T構建體、具有新標靶的雙特異性抗體和抗體藥物複合體。

各公司正大力投資大規模臨床試驗，以推進藥物進入早期治療階段，並在治療序列中佔據主導地位。現有藥物的生命週期管理也是一項關鍵策略，目前正在進行新型聯合治療的研究和皮下製劑的開發。大型製藥企業與生技創新者之間的合作和授權協議也十分普遍，加速了藥物的研發和商業化進程。

未來市場趨勢

多發性骨髓瘤市場的未來發展方向是：採用日益精細化的免疫療法，以功能性治癒為治療目標，並制定更個人化的治療方案。針對BCMA以外的新標靶的新型態治療方法研發工作已經展開。將細胞療法和雙特異性抗體整合到第一線治療方案中，將重新定義多發性骨髓瘤的治療標準。

市場參與企業要想取得長期成功，需要在競爭激烈的市場環境中展現卓越的療效和可控的安全性，成功應對高成本治療的複雜報銷流程，並製定應對抗藥性的策略。作為腫瘤學領域的創新典範，多發性骨髓瘤市場以持續的科學進步為特徵，旨在將曾經令人絕望的疾病轉變為一種可控的慢性疾病，從而確保其持續發展和進步。

本報告的主要優勢：

深入分析：獲得主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
市場促進因素與未來趨勢：探索市場促進因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用這些見解，在快速變化的環境中製定策略決策，發展新的商業機會和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

以下是一些公司如何使用這份報告的範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2022年至2024年的歷史數據和2025年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

介紹
北美洲
- 按類型
- 透過治療方法
- 透過診斷
- 最終用戶
- 按國家/地區
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 按類型
- 透過治療方法
- 透過診斷
- 最終用戶
- 按國家/地區
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 按類型
- 透過治療方法
- 透過診斷
- 最終用戶
- 按國家/地區
  - 英國
  - 德國
  - 法國
  - 西班牙
  - 其他
中東和非洲
- 按類型
- 透過治療方法
- 透過診斷
- 最終用戶
- 按國家/地區
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 其他
亞太地區
- 按類型
- 透過治療方法
- 透過診斷
- 最終用戶
- 按國家/地區
  - 中國
  - 日本
  - 印度
  - 韓國
  - 台灣
  - 其他

第10章競爭格局與分析

主要企業和策略分析
市佔率分析
合併、收購、協議和合作
競爭對手儀錶板

第11章公司簡介

Revlimid
Bristol-Myers Squibb
Abecma
Novartis
Pomalyst
Takeda Pharmaceuticals
Johnson & Johnson
Innate Pharma
Janssen

第12章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
調查方法
簡稱

簡介目錄

Product Code: KSI061616015

Multiple Myeloma Market is projected to expand at a 6.22% CAGR, reaching USD 37.67 billion in 2031 from USD 26.231 billion in 2025.

The multiple myeloma market represents a dynamic and rapidly evolving segment within hematological oncology, focused on a malignancy of plasma cells in the bone marrow. Characterized by a high relapse rate and the development of treatment resistance, the disease necessitates a continuous pipeline of novel therapeutic approaches, making this market a hub for significant clinical research and pharmaceutical investment.

Core Clinical Challenge and Therapeutic Paradigm

Multiple myeloma remains an incurable but increasingly treatable cancer, with management strategies centered on achieving deep and durable remissions, controlling symptoms, and preserving quality of life. The therapeutic landscape has shifted dramatically from reliance on traditional chemotherapy and corticosteroids to a multifaceted arsenal including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and, most recently, advanced cellular and bispecific immunotherapies. Treatment is typically administered in sequences, with regimens selected based on patient fitness, disease risk stratification, and prior therapy, reflecting a complex and personalized approach to care.

Primary Market Growth Drivers

Market expansion is fundamentally driven by the rising global incidence of the disease, which is strongly correlated with an aging population. As the predominant risk factor, increasing age ensures a growing addressable patient population, particularly in developed economies with aging demographics. This demographic trend provides a sustained baseline demand for effective therapies.

The most powerful growth vector, however, is the accelerated pace of therapeutic innovation and new drug approvals. The regulatory landscape has been highly active, with approvals for novel mechanisms of action, including B-cell maturation antigen (BCMA)-targeted therapies such as bispecific T-cell engagers and chimeric antigen receptor (CAR) T-cell therapies. These approvals continually expand the treatment repertoire for relapsed/refractory disease and are progressively moving into earlier lines of therapy, significantly lengthening treatment pathways and driving market value.

Increased disease awareness and earlier diagnosis also contribute to market growth. Educational initiatives by patient advocacy groups and professional societies have improved recognition of symptoms among primary care providers and the public, leading to earlier specialist referral and diagnosis. Earlier intervention in the disease course expands the window for effective treatment and improves long-term outcomes, thereby integrating more patients into active, long-term management pathways.

Substantial and ongoing investment in biomedical research underpins the market's evolution. A deepening understanding of disease biology, tumor microenvironment interactions, and mechanisms of resistance is translating into a rich pipeline of targeted agents and immunotherapies. This research is supported by significant funding from both public institutions and private pharmaceutical companies, fostering a competitive and innovative environment.

Market Opportunities and Evolving Frontiers

Key opportunities for future growth lie in several areas. The frontier of treatment is increasingly focused on earlier lines of therapy, including newly diagnosed and even high-risk smoldering myeloma, aiming to prevent progression. The development of personalized treatment strategies, guided by genomic profiling and minimal residual disease (MRD) monitoring, represents a major opportunity to optimize outcomes and tailor therapy intensity.

Furthermore, the market is poised for expansion through improved access and adoption in emerging economies, where diagnosis and treatment infrastructure are developing. The exploration of novel drug combinations and sequencing strategies to overcome resistance and deepen responses remains a central focus of clinical development.

Market Restraints and Clinical Hurdles

The market faces significant inherent challenges. The development of treatment resistance remains a fundamental biological obstacle, limiting the long-term efficacy of all current therapies and necessitating a continuous pipeline of novel agents. The complexity and heterogeneity of the disease, with numerous genetic subtypes, complicate the development of universally effective treatments.

Furthermore, the toxicity profiles of newer, more potent therapies-including cytokine release syndrome, neurotoxicity, and prolonged cytopenias-present substantial management challenges. These toxicities can impact patient quality of life, require specialized clinical support, and limit the applicability of therapies in frail or elderly populations.

Geographic Landscape and Regional Dynamics

North America maintains a leadership position in the global multiple myeloma market. This is attributable to a high disease prevalence, a robust clinical trial infrastructure that facilitates rapid adoption of new therapies, favorable reimbursement landscapes, and the presence of leading research institutions and pharmaceutical companies. The region often serves as the initial launch market and primary revenue generator for innovative, high-cost therapies.

Competitive Landscape and Strategic Focus

The competitive environment is intense and features both large multinational pharmaceutical companies and specialized biotechnology firms. Strategic activities are centered on extensive research and development to advance next-generation therapies, including novel CAR-T constructs, bispecific antibodies with new targets, and antibody-drug conjugates.

Companies are heavily invested in large-scale clinical trials to move their agents into earlier treatment lines and secure dominant positions in therapeutic sequences. Lifecycle management for established drugs, through new combination studies or subcutaneous formulations, is also a key strategy. Collaboration and licensing agreements between large pharma and biotech innovators are common, accelerating development and commercialization.

Future Market Trajectory

The future trajectory of the multiple myeloma market is oriented toward increasingly sophisticated immunotherapy, functional cure as a treatment goal, and greater personalization. The development of therapies with novel targets beyond BCMA is already underway. The integration of cellular therapies and bispecific antibodies into first-line treatment paradigms will redefine standards of care.

Long-term success for market participants will depend on demonstrating superior efficacy and manageable safety in competitive landscapes, navigating complex reimbursement pathways for high-cost therapies, and developing strategies to address treatment resistance. As a model for innovation in oncology, the multiple myeloma market is characterized by relentless scientific advancement aimed at transforming a once devastating diagnosis into a chronic, manageable condition, ensuring its continued expansion and evolution.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2022 to 2024 & forecast data from 2025 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Multiple Myeloma Market Segmentation

By Type
Smouldering Multiple Myeloma
Active Multiple Myeloma
By Treatment
Chemotherapy
Targeted Therapy
Immunotherapy
Stem Cell Transplantation
Corticosteroids
By Diagnosis
Blood Tests
Bone Marrow Biopsy
Urine Tests
By End-User
Hospitals & Clinics
Homecare
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
India
South Korea
Taiwan
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MULTIPLE MYELOMA MARKET BY TYPE

5.1. Introduction
5.2. Smouldering Multiple Myeloma
5.3. Active Multiple Myeloma

6. MULTIPLE MYELOMA MARKET BY TREATMENT

6.1. Introduction
6.2. Chemotherapy
6.3. Targeted Therapy
6.4. Immunotherapy
6.5. Stem Cell Transplantation
6.6. Corticosteroids

7. MULTIPLE MYELOMA MARKET BY DIAGNOSIS

7.1. Introduction
7.2. Blood Tests
7.3. Bone Marrow Biopsy
7.4. Urine Tests

8. MULTIPLE MYELOMA MARKET BY END-USER

8.1. Introduction
8.2. Hospitals & Clinics
8.3. Homecare
8.4. Others

9. MULTIPLE MYELOMA MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. By Type
- 9.2.2. By Treatment
- 9.2.3. By Diagnosis
- 9.2.4. By End-User
- 9.2.5. By Country
  - 9.2.5.1. USA
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. South America
- 9.3.1. By Type
- 9.3.2. By Treatment
- 9.3.3. By Diagnosis
- 9.3.4. By End-User
- 9.3.5. By Country
  - 9.3.5.1. Brazil
  - 9.3.5.2. Argentina
  - 9.3.5.3. Others
9.4. Europe
- 9.4.1. By Type
- 9.4.2. By Treatment
- 9.4.3. By Diagnosis
- 9.4.4. By End-User
- 9.4.5. By Country
  - 9.4.5.1. United Kingdom
  - 9.4.5.2. Germany
  - 9.4.5.3. France
  - 9.4.5.4. Spain
  - 9.4.5.5. Others
9.5. Middle East and Africa
- 9.5.1. By Type
- 9.5.2. By Treatment
- 9.5.3. By Diagnosis
- 9.5.4. By End-User
- 9.5.5. By Country
  - 9.5.5.1. Saudi Arabia
  - 9.5.5.2. UAE
  - 9.5.5.3. Others
9.6. Asia Pacific
- 9.6.1. By Type
- 9.6.2. By Treatment
- 9.6.3. By Diagnosis
- 9.6.4. By End-User
- 9.6.5. By Country
  - 9.6.5.1. China
  - 9.6.5.2. Japan
  - 9.6.5.3. India
  - 9.6.5.4. South Korea
  - 9.6.5.5. Taiwan
  - 9.6.5.6. Others